Alnylam Partners with Viz.ai and American Heart Association to Tackle ATTR-CM Underdiagnosis
Event summary
- Alnylam collaborates with Viz.ai to develop an AI-enabled ATTR-CM care pathway using FDA-cleared echocardiography AI algorithm Us2.ai.
- AWARE study launched at five pilot health systems to evaluate AI-enabled screening integration and impact on diagnostic timelines.
- Alnylam supports a three-year American Heart Association initiative to strengthen ATTR-CM care systems across 10 health systems.
- Efforts aim to address underdiagnosis and fragmented care in ATTR-CM, a rapidly progressive, life-threatening cause of heart failure.
The big picture
Alnylam's strategic initiatives with Viz.ai and the American Heart Association reflect a broader industry trend towards leveraging AI and system-level partnerships to improve diagnostic accuracy and care coordination in rare diseases. The focus on ATTR-CM underscores the growing emphasis on early intervention in progressive, life-threatening conditions. These efforts aim to address significant gaps in current care pathways, potentially transforming patient outcomes and setting a precedent for other underdiagnosed conditions.
What we're watching
- AI Integration
- How the AWARE study will impact the adoption of AI tools in real-world clinical settings for ATTR-CM diagnosis.
- Care Coordination
- Whether the American Heart Association's national learning collaborative can successfully scale best practices for ATTR-CM management.
- Diagnostic Timelines
- The pace at which AI-enabled detection and coordinated care pathways can reduce the time to diagnosis for ATTR-CM patients.